NuCana PLC (NCNA)
1.55
-0.03
(-1.90%)
USD |
NASDAQ |
Nov 14, 16:00
1.555
0.00 (0.00%)
After-Hours: 20:00
NuCana Research and Development Expense (Quarterly): 8.540M for June 30, 2024
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2024 | 8.540M |
| March 31, 2024 | 8.604M |
| December 31, 2023 | 8.519M |
| September 30, 2023 | 9.420M |
| June 30, 2023 | 4.955M |
| March 31, 2023 | 8.272M |
| December 31, 2022 | 15.51M |
| September 30, 2022 | 8.693M |
| June 30, 2022 | 8.053M |
| March 31, 2022 | 12.67M |
| December 31, 2021 | 14.34M |
| September 30, 2021 | 12.37M |
| June 30, 2021 | 11.91M |
| March 31, 2021 | 12.00M |
| December 31, 2020 | 10.53M |
| Date | Value |
|---|---|
| September 30, 2020 | 7.905M |
| June 30, 2020 | 7.271M |
| March 31, 2020 | 7.611M |
| December 31, 2019 | 6.669M |
| September 30, 2019 | 5.970M |
| June 30, 2019 | 6.883M |
| March 31, 2019 | 5.667M |
| December 31, 2018 | 5.982M |
| September 30, 2018 | 4.342M |
| June 30, 2018 | 7.029M |
| March 31, 2018 | 5.152M |
| December 31, 2017 | 5.055M |
| September 30, 2017 | 13.32M |
| June 30, 2017 | 2.655M |
| March 31, 2017 | 1.996M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
4.955M
Minimum
Jun 2023
15.51M
Maximum
Dec 2022
9.676M
Average
8.604M
Median
Mar 2024
Research and Development Expense (Quarterly) Benchmarks
| Adaptimmune Therapeutics PLC | 40.45M |
| Biodexa Pharmaceuticals PLC | -- |
| Verona Pharma PLC | 10.55M |
| Autolus Therapeutics PLC | 36.61M |
| Mereo BioPharma Group PLC | 4.946M |